OpGen, Inc., a leading player in the genomics and molecular diagnostics industry, is headquartered in the United States. Founded in 2001, the company has established itself as a pioneer in the development of innovative solutions for infectious disease management and antibiotic resistance. With a focus on utilising advanced genomic technologies, OpGen offers unique products such as the Acuitas® MDRO Gene Test, which enables rapid detection of multidrug-resistant organisms. The company operates primarily in North America and Europe, positioning itself as a key contributor to the fight against antimicrobial resistance. OpGen's commitment to enhancing patient outcomes through precise diagnostics has garnered recognition within the healthcare community, solidifying its market position as a trusted provider of genomic insights. With a robust portfolio of services, OpGen continues to lead the way in transforming the landscape of infectious disease diagnostics.
How does OpGen, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
OpGen, Inc.'s score of 23 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
OpGen, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and commitments suggests that OpGen may not yet have established a formal framework for addressing its carbon footprint or engaging in climate action initiatives. As the industry increasingly prioritises sustainability, it will be essential for OpGen to consider developing and communicating its climate commitments to align with best practices and stakeholder expectations.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
OpGen, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

